Progenics Pharma (PGNX) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of $0.52, $0.03 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $53.9 million versus the consensus estimate of $52.9 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
- Compass Diversified (CODI) Misses Q3 EPS by 2c
- UWM Holdings Corporation (UWMC) Reports Q3 results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
